180 related articles for article (PubMed ID: 9615912)
1. Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
Hillebrant CG; Axelson M; Björkhem I; Wang FH; Nyberg B; Einarsson C
Eur J Clin Invest; 1998 Apr; 28(4):324-8. PubMed ID: 9615912
[TBL] [Abstract][Full Text] [Related]
2. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
[TBL] [Abstract][Full Text] [Related]
3. Changes in biliary lipid output after interruption of pravastatin treatment in humans.
Hillebrant CG; Eriksson M; Nyberg B; Einarsson K
Eur J Clin Invest; 1996 Dec; 26(12):1160-5. PubMed ID: 9013093
[TBL] [Abstract][Full Text] [Related]
4. Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.
Yoshida T; Honda A; Shoda J; Abei M; Matsuzaki Y; Tanaka N; Miyazaki H; Osuga T
Lipids; 1997 Aug; 32(8):873-8. PubMed ID: 9270980
[TBL] [Abstract][Full Text] [Related]
5. [Effect of pravastatin on hepatic cholesterol metabolism].
Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
Fortschr Med; 1991 Mar; 109(8):189-94. PubMed ID: 1905265
[TBL] [Abstract][Full Text] [Related]
6. Circulating markers for biosynthesis of cholesterol and bile acids are not depressed in asymptomatic gallstone subjects.
Muhrbeck O; Wang FH; Björkhem I; Axelson M; Einarsson K
J Hepatol; 1997 Jul; 27(1):150-5. PubMed ID: 9252089
[TBL] [Abstract][Full Text] [Related]
7. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
Okamoto S; Nakano K; Kosahara K; Kishinaka M; Oda H; Ichimiya H; Chijiiwa K; Kuroki S
J Gastroenterol; 1994 Feb; 29(1):47-55. PubMed ID: 8199696
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A.
Regazzi MB; Iacona I; Campana C; Gavazzi A; Viganò M; Perani G
Transplant Proc; 1994 Oct; 26(5):2644-5. PubMed ID: 7940825
[No Abstract] [Full Text] [Related]
9. Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver.
Carrella M; Fong LG; Loguercio C; Del Piano C
Metabolism; 1999 May; 48(5):618-26. PubMed ID: 10337863
[TBL] [Abstract][Full Text] [Related]
10. Pravastatin sodium, an inhibitor of HMG-CoA reductase, decreases HDL cholesterol by transfer of cholesteryl ester from HDL to VLDL in Japanese white rabbits.
Miyazaki A; Koieyama T; Shimada Y; Kikuchi T; Ito K; Kasanuki N; Koga T
J Atheroscler Thromb; 2004; 11(1):22-8. PubMed ID: 15067195
[TBL] [Abstract][Full Text] [Related]
11. Effect of chenodeoxycholic acid and phenobarbital on the rate-limiting enzymes of hepatic cholesterol and bile acid synthesis in patients with gallstones.
Coyne MJ; Bonorris GG; Goldstein LI; Schoenfield LJ
J Lab Clin Med; 1976 Feb; 87(2):281-91. PubMed ID: 1245792
[TBL] [Abstract][Full Text] [Related]
12. Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones.
Smith JL; Roach PD; Wittenberg LN; Riottot M; Pillay SP; Nestel PJ; Nathanson LK
J Gastroenterol Hepatol; 2000 Aug; 15(8):871-9. PubMed ID: 11022827
[TBL] [Abstract][Full Text] [Related]
13. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.
Smit JW; van Erpecum KJ; Renooij W; Stolk MF; Edgar P; Doornewaard H; Vanberge-Henegouwen GP
Hepatology; 1995 Jun; 21(6):1523-9. PubMed ID: 7768495
[TBL] [Abstract][Full Text] [Related]
14. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans.
Kallien G; Lange K; Stange EF; Scheibner J
Hepatology; 1999 Jul; 30(1):14-20. PubMed ID: 10385633
[TBL] [Abstract][Full Text] [Related]
15. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia.
Jacob BG; Möhrle W; Richter WO; Schwandt P
Eur J Clin Pharmacol; 1992; 42(4):353-8. PubMed ID: 1516599
[TBL] [Abstract][Full Text] [Related]
16. Hepatic cholesterol and bile acid synthesis in Japanese patients with cholesterol gallstones.
Honda A; Yoshida T; Tanaka N; Matsuzaki Y; He B; Osuga T; Kobayashi N; Ozawa K
Gastroenterol Jpn; 1993 Jun; 28(3):406-14. PubMed ID: 8344502
[TBL] [Abstract][Full Text] [Related]
17. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.
Hillebrant CG; Nyberg B; Gustafsson U; Sahlin S; Björkhem I; Rudling M; Einarsson C
Eur J Clin Invest; 2002 Jul; 32(7):528-34. PubMed ID: 12153554
[TBL] [Abstract][Full Text] [Related]
18. Lifibrol as a model compound for a novel lipid-lowering mechanism of action.
Berthold HK; Sudhop T; von Bergmann K; Gouni-Berthold I
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):364-72. PubMed ID: 20693157
[TBL] [Abstract][Full Text] [Related]
19. The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans.
Hillebrant CG; Nyberg B; Einarsson K; Eriksson M
Gut; 1997 Nov; 41(5):700-4. PubMed ID: 9414982
[TBL] [Abstract][Full Text] [Related]
20. Pravastatin sodium, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, decreases serum total cholesterol in Japanese White rabbits by two different mechanisms.
Miyazaki A; Koga T
Atherosclerosis; 2002 Jun; 162(2):299-306. PubMed ID: 11996949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
